Shots:
- Voro Therapeutics & Alloy Therapeutics have entered into a strategic research collaboration to discover and develop next-generation masked T-cell engager (TCE) therapies
- Partnership will combine Voro’s PrimeBody platform with Alloy’s optimized CD3 antibodies & multispecific engineering capabilities to develop novel immunotherapies designed to selectively activate immune responses within tumors
- PrimeBody is designed to unlock difficult-to-target diseases by selectively activating biologics within diseased tissue, reducing systemic toxicity and expanding the therapeutic potential of conventional biologics
Ref: Businesswire | Image: Voro & Alloy | Press Release
Related News: LabGenius Therapeutics and LG Chem Collaborate to Develop an AI/ML-Designed Tumour-Targeting Antibody
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
